Search

Your search keyword '"Lopez-Palop, Ramon"' showing total 184 results
Start Over Author "Lopez-Palop, Ramon"
184 results on '"Lopez-Palop, Ramon"'

54. Thrombosis of Second-Generation Drug-Eluting Stents in Real Practice: Results From the Multicenter Spanish Registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2)

Author

de la Torre Hernández, José M., Alfonso, Fernando, Gimeno, Federico, Diarte, Jose A., Lopez-Palop, Ramón, Pérez de Prado, Armando, Rivero, Fernando, Sanchis, Juan, Larman, Mariano, Diaz, Jose F., Elizaga, Jaime, Moreiras, Javier Martín, Gomez Jaume, Alfredo, Hernández, José M., Mauri, Josepa, Recalde, Angel Sánchez, Bullones, Juan A., Rumoroso, Jose R., del Blanco, Bruno García, Baz, Jose A., Bosa, Francisco, Botas, Javier, and Hernández, Felipe

Published
2010
Full Text
View/download PDF

59. El anciano con cardiopatía terminal

Author

Martínez-Sellés, Manuel, Teresa Vidán, María, López-Palop, Ramón, Rexach, Lourdes, Sánchez, Elisabet, Datino, Tomás, Cornide, María, Carrillo, Pilar, Ribera, José M., Díaz-Castro, Óscar, and Bañuelos, Camino

Published
2009
Full Text
View/download PDF

61. End-Stage Heart Disease in the Elderly

Author

Martínez-Sellés, Manuel, Teresa Vidán, María, López-Palop, Ramón, Rexach, Lourdes, Sánchez, Elisabet, Datino, Tomás, Cornide, María, Carrillo, Pilar, Ribera, José M., Díaz-Castro, Óscar, and Bañuelos, Camino

Published
2009
Full Text
View/download PDF

73. Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents: EPIC05-Sierra75 study.

Author

de la Torre Hernandez, Jose M., Lopez Palop, Ramon, Jimenez Mazuecos, Jesus M., Carrillo Sáez, Pilar, Gutierez-Barrios, Alejandro, Pinar, Eduardo, Cid, Belen, Fernandez, Luis, Garcia Camarero, Tamara, Urbano-Carrillo, Cristóbal, Oteo Dominguez, Juan F., Jimenez Diaz, Victor A., Gomez Menchero, Antonio E., Galindo Fernández, Eladio, Córdoba Soriano, Juan G., Ocaranza, Raymundo, Arroyo Úcar, Eduardo, San Roman, Koldobika Garcia, Leal, Silvio, and Martínez Cáceres, Ginés

Subjects
HEMORRHAGE risk factors, THERAPEUTIC use of fibrinolytic agents, ISCHEMIA, RESEARCH, CARDIOVASCULAR diseases risk factors, SAFETY, PERCUTANEOUS coronary intervention, REVASCULARIZATION (Surgery), DRUG-eluting stents, LOG-rank test, DISEASE incidence, MYOCARDIAL infarction, CASE-control method, RETROSPECTIVE studies, FISHER exact test, MEDICAL protocols, RISK assessment, EVEROLIMUS, CARDIAC arrest, DESCRIPTIVE statistics, CHI-squared test, KAPLAN-Meier estimator, DATA analysis software, HEMORRHAGE, LONGITUDINAL method, PROPORTIONAL hazards models, DISEASE risk factors, OLD age
Abstract

OBJECTIVES Elderly patients show a higher incidence of ischemic and bleeding events after percutaneous transluminal coronary intervention (PCI). We sought to investigate outcomes in elderly patients treated with antithrombotic strategy guided by bleeding and ischemic risks after revascularization with last generation everolimus-eluting stent (EES). METHODS Prospective multicenter registry including patients over 75 years revascularized with EES and antithrombotic therapy guided by clinical presentation, PCI complexity and PRECISE DAPT score. Co-primary safety endpoints were: (1) composite of cardiac death, myocardial infarction and stent thrombosis and; (2) bleeding (BARC 2-5). Primary efficacy endpoint was target lesion revascularization. A matched group of patients revascularized with current drug-eluting stents and no such tailored antithrombotic therapy was used as control. RESULTS Finally, 1064 patients were included in SIERRA-75 cohort, 80.8 ± 4.2 years, 36.6% women, 71% acute coronary syndromes (ACS) and 53.6% complex PCI. Co-primary safety endpoint of major adverse cardiovascular events was met in 6.2%, coprimary safety endpoint of bleeding in 7.8% and primary efficacy endpoint of TKLR in 1.5%. The multivariable adjusted model showed no significant association of the prescribed short/long dual antiplatelet therapy (DAPT) durations with any endpoint suggesting a well tailored therapy. No stent thrombosis reported in the subgroup with 1-3 months DAPT duration. As compared to control group, bleeding BARC 2-5 was significantly lower in SIERRA-75 group (7.4% vs. 10.2%, P = 0.04) as well as the net safety-efficacy endpoint (14.3% vs. 18.5%, P = 0.02). CONCLUSIONS In elderly population, the application of this risks-adjusted antithrombotic protocol after revascularization with last generation EES seems to be associated with an improved prognosis in terms of ischemic and bleeding outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results